Clinical trial
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients…
NCT00106301 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00106301 |
|---|---|
| Title | Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 |
| Official title | A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Have Completed a Prior Clinical Study With FK228 |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell, Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | FK228 (romidepsin) |
| Enrollment | 2 |
| Start date | Apr 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Mar 23, 2005 |
| Last update posted | Nov 18, 2019 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: